Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea in diabetic macular edema
NCT02392364Phase 4Completed
- Sponsor
- California Retina Consultants
- Start
- Apr 2015
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in diabetic macular edema (DME), sponsored by California Retina Consultants. Started Apr 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02392364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392364.